MedTrace Logo

Risk Factors for Postpartum Hemorrhage

NCT06730919 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-10-01

No results posted yet for this study

Summary

Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including PPH, preeclampsia, thromboembolism, abortion, and intrauterine growth restriction. The incidence of PPH in women with systemic lupus erythematosus (SLE) has been reported to be as high as 34%. However, few studies have investigated PPH risk factors in pregnant women with systemic autoimmune disease. Therefore, the purpose of this study is to investigate the incidence and related risk factors of PPH in pregnant women with systemic autoimmune disease, and to provide the latest evidence for further study on prevention of PPH in women at high risk of PPH.

Conditions

  • Postpartum Hemorrhage
  • Systemic Autoimmune Diseases

Interventions

DIAGNOSTIC_TEST

Estimated Blood Loss after cesarean delivery within 24 h

The total estimated blood loss was calculated by equation: Estimated Blood Loss (EBL) = EBV ×((HCT1 - HCT2)/(HCT mean)), EBV = Estimated Blood volume; whereas EBV = Patient's weight (in kilogram) × 70 mL/kg, HCT1=preoperative hematocrit, HCT2 = postoperative hematocrit, and HCT mean = (HCT1 + HCT2)/2

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Jie Xiao, PHD · Renji Hospital, Shanghai Jiaotong University, School of Medcine

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2024-06-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06730919 on ClinicalTrials.gov